Genetic and Mutational Analyses of a Large Multiethnic Bardet-Biedl Cohort Reveal a Minor Involvement of BBS6 and Delineate the Critical Intervals of Other Loci  by Beales, Philip L. et al.
Am. J. Hum. Genet. 68:606–616, 2001
606
Genetic and Mutational Analyses of a Large Multiethnic Bardet-Biedl
Cohort Reveal a Minor Involvement of BBS6 and Delineate the Critical
Intervals of Other Loci
Philip L. Beales,1,6,* Nicholas Katsanis,1,* Richard A. Lewis,1,2,3,4,5 Stephen J. Ansley,1
Nursel Elcioglu,7 Jamal Raza,8 Michael O. Woods,9 Jane S. Green,9 Patrick S. Parfrey,9
William S. Davidson,10 and James R. Lupski1,4
Departments of 1Molecular and Human Genetics, 2Ophthalmology, 3Medicine, and 4Pediatrics, and the 5Cullen Eye Institute, Baylor College
of Medicine, Houston; 6Molecular Medicine Unit, Institute of Child Health, University College London, London; 7Department of Pediatric
Genetics, University Hospital, Istanbul; 8National Institute of Child Health, Karachi, Pakistan; 9Faculty of Medicine, Memorial University of
Newfoundland, St. John’s, Newfoundland; 10Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British
Columbia
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized primarily by obesity, polydactyly,
retinal dystrophy, and renal disease. The significant genetic and clinical heterogeneity of this condition have sub-
stantially hindered efforts to positionally clone the numerous BBS genes, because the majority of available pedigrees
are small and the disorder cannot be assigned to any of the six known BBS loci. Consequently, the delineation of
critical BBS intervals, which would accelerate the discovery of the underlying genetic defect(s), becomes difficult,
especially for loci with minor contributions to the syndrome. We have collected a cohort of 163 pedigrees from
diverse ethnic backgrounds and have evaluated them for mutations in the recently discovered BBS6 gene (MKKS)
on chromosome 20 and for potential assignment of the disorder to any of the other known BBS loci in the human
genome. Using a combination of mutational and haplotype analysis, we describe the spectrum of BBS6 alterations
that are likely to be pathogenic; propose substantially reduced critical intervals for BBS2, BBS3, and BBS5; and
present evidence for the existence of at least one more BBS locus. Our data also suggest that BBS6 is a minor
contributor to the syndrome and that some BBS6 alleles may act in conjunction with mutations at other BBS loci
to cause or modify the BBS phenotype.
Introduction
Positional cloning has proven successful in the identifi-
cation of genes for monogenic disorders. However, the
presence of genetic heterogeneity often complicates such
efforts, particularly for rare recessive disorders. Bardet-
Biedl syndrome (BBS [MIM 209900]) exemplifies such
instances. BBS is a multisystem autosomal recessive dis-
order characterized by rod-cone dystrophy, polydactyly,
central obesity, hypogonadism, learning difficulties, and
renal dysplasia. Other features that vary in frequency
include diabetes mellitus, hepatic fibrosis, reproductive
abnormalities, endocrinologic deficiencies, short stature,
developmental retardation, and speech and behavioral
abnormalities (Green et al. 1989; Beales et al. 1999).
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The estimated population prevalence varies from 1/
13,500 among the Bedouin of Kuwait (Farag and Teebi
1989) to 1/160,000 in Western Europe (Klein and Am-
mann 1969).
Six BBS loci have been identified to date: BBS1 on
11q13 (Leppert et al. 1994), BBS2 on 16q21 (Kwitek-
Black et al. 1993), BBS3 on 3p12-13 (Sheffield et al.
1994), BBS4 on 15q23 (Carmi et al. 1995b), BBS5 on
2q31 (Young et al. 1999a), and BBS6 on 20p12 (Kat-
sanis et al. 2000; Slavotinek et al. 2000). However, only
one BBS gene has been cloned (BBS6/MKKS) (Katsanis
et al. 2000; Slavotinek et al. 2000). Furthermore, despite
some efforts to assign clinically this variable phenotype
to the different genetic loci, data correlating specific
phenotypic features with individual BBS genes have
been inconclusive (Carmi et al. 1995a; Beales et al.
1997; Young et al. 1998). Thus, in the absence of either
large families or pedigrees from population isolates, ge-
netic analysis of unrelated families remains the only re-
liable means of differentiating loci (Carmi et al. 1995a;
Beales et al. 1997; Bruford et al. 1997; Young et al.
1998, 1999b; Katsanis et al. 1999; Woods et al. 1999).
Three studies have attempted to assay the distribution
of the BBS loci (Beales et al. 1997; Bruford et al. 1997;
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Katsanis et al. 1999). BBS1 accounts for the disorder
in 36%–56% of pedigrees, BBS2 in 24%–27% of ped-
igrees, and BBS4 in 32%–35% of pedigrees. Only a
single verification of the BBS3 interval, in a Newfound-
land kindred, has been reported previously, bringing the
total number of families in which the disorder maps to
that locus to two (Sheffield et al. 1994; Young et al.
1998). The existence of BBS5 on 2q31 (Young et al.
1999a) has yet to be confirmed independently. BBS6 on
20p12-p13 was also recently identified, and mutations
in the McKusick-Kaufman syndrome gene (MKKS;
Stone et al. 2000) were described for this locus (Katsanis
et al. 2000; Slavotinek et al. 2000).
We present here the results of a screen for MKKS
mutations in 163 pedigrees with BBS, and we appraise
the contribution of known BBS loci in the North Amer-
ican/northern European populations with a combina-
torial strategy of linkage disequilibrium and haplotype
analysis. Unlike the distribution of BBS disease alleles
in Newfoundland, where BBS6 is nearly as common as
BBS1 (Katsanis et al. 2000), linkage to BBS6was found
in only ∼4% of pedigrees from our more diverse cohort.
We also report data from North American, European,
Turkish, Iraqi, Pakistani, and Indian populations that
reduce substantially two of the four critical intervals,
potentially rendering them amenable to positional clon-
ing, and we report mapping of BBS to BBS5 on 2q31
in three families, the first independent evidence sup-
porting the existence of this locus. Finally, we demon-
strate, in several pedigrees, the exclusion of all known
BBS loci, and we suggest that at least a seventh, yet
unmapped, locus exists in the human genome.
Patients and Methods
One hundred sixty-three BBS pedigrees were screened for
mutations inMKKS. Fifty pedigrees (27 North American/
European and 2Newfoundland pedigrees forwhichBBS1
was excluded through haplotype analysis, and 21 con-
sanguineous pedigrees of Turkish, Iraqi, Pakistani, and
Indian origin) were included in linkage analyses. The di-
agnosis of BBS was based on established criteria in which
three of six cardinal features must be present (Beales et
al. 1999). In several cases, the diagnosis was ascertained
by local physicians and verified through extensive ex-
amination of medical records by one ormore of us (P.L.B.,
R.A.L., J.S.G., or P.S.P.).
Blood was obtained, with informed consent, in accord
with protocols approved by the appropriate oversight
committees at each institution, and DNA was extracted
by a salting-out process (Puregene, Gentra Systems). Di-
rect sequencing of MKKS was performed as described
elsewhere (Katsanis et al. 2000). MKKS primers for mu-
tational analysis can be retrieved from the Lupski lab
home page. For the genetic analyses, a total of 54 custom-
synthesized (MWG/Sigma-Genosys) fluorescent micro-
satellite STRPs were typed for each family member: for
BBS1: D11S4205, D11S1883, D11S599, D11S449,
D11S1889, D11S4909, D11S4946, PYGM, D11S4945,
and D11S4944; for BBS2: D16S411, D16S415,
D16S419, D16S390, D16S408, D16S526, D16S3089,
D16S265, D16S3034, D16S408, D16S3057, D16S514,
D16S503, D16S400, D16S421, and D16S515; for
BBS3: D3S1566, D3S1276, D3S3634, D3S1603,
D3S1251, D3S2419, D3S1271, and D3S1278; for
BBS4: D15S117, D15S153, D15S125, D15S988,
D15S814,D15S650,D15S131D15S204,D15S114, and
D15S205; for BBS5: D2S151, D2S142, D2S156,
D2S2330, D2S335, and D2S326; and for BBS6:
D20S115, D20S851, D20S189, and D20S186. Primer
sequences were obtained through the Genome Database
or the MIT Center for Genome Research. All DNA
samples were adjusted to 30 ng/ml, and PCR reactions
were performed on an MJR Tetrad or an MWG Primus
thermocycler. Products were resolved on an ABI 377
automated sequencer, and alleles were assigned with
GENESCANv2.3 andGENOTYPER v2.1 software (Ap-
plied Biosystems). Sequence data were managed on Se-
quencher (GenecodesCorporation). Linkage analysiswas
performed, where appropriate, with the LINKAGEpack-
age of programs: two-point linkage data were generated
with MLINK (assuming a gene frequency of .005 and a
penetrance of .9); multipoint analyses were performed
with LINKMAP.
Results
Mutation Analysis of MKKS (20p12)
We sequenced the open reading frame (ORF) ofMKKS
in all 163 pedigrees regardless of their haplotype-inferred
locus assignment. In eight pedigrees, we identified mis-
sense alterations that segregate with the disease (table
1). These were not present in a minimum of 188 chro-
mosomes from matched control populations. In contrast
to previous findings, in which most disease-causing mu-
tations were frameshifts (Katsanis et al. 2000; Slavotinek
et al. 2000), all changes identified in this survey resulted
in missense alterations that may affect the solubility and/
or the structure of theMKKS protein (table 1).We found
no alterations in either exon 4 or exon 5 ofMKKS,which
suggests that mutations in that region of the molecule
may be nonpathogenic, may not result in BBS, or may
be too severe to allow viability of the embryo. We did,
however, detect three changes in exon 6 that would affect
the C-terminus of MKKS. Evaluation of the clinical phe-
notype in these patients did not reveal substantial dif-
ferences from the other BBS pedigrees, although the
numbers are too small to allow meaningful conclusions.
The A242S change that we describe in family NF-B14
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Table 1
MKKS Nucleotide Alterations Found Exclusively in Patients with BBS
Pedigree Exon Alteration Potential Consequence
NF-B14 3 A242S Also reported in MKKS family (Stone et al. 1999)
AR-259 3 Q147X Change to stop codon–truncated protein
AR-301 3 T57A Potential solubility change
AR-396 3 I32M Start methionine introduced in good Kozak context
AR-396 3 S235P Insertion of kink in a helix
AR-127 3 D285A Potential solubility change
KK-062 6 R518H Unknown
AR-579 6 C499S Secondary structure change
AR-017 6 S511A Potential solubility change
has been shown to cause disease in conjunction with
an H84Y mutation. This complex homozygous H84Y/
A242S allele results in McKusick-Kaufman syndrome in
the OldOrder Amish (Stone et al. 2000).Wewere unable
to find the second mutant allele in family B14, but hap-
lotype analysis with microsatellites across the BBS6
region demonstrated that the two sibs have identical
20p12 haplotypes. Notably, the affected sib in this ped-
igree is homozygous for markers across the BBS2 critical
interval on 16q21 (fig. 1). The A242S alteration was
found once in 142 Newfoundland control chromosomes
and in none of 188 North American/European control
chromosomes, suggesting either that it is a very rare
polymorphism or that its involvement in the disease does
not follow a classical model of recessive inheritance.
Distribution of BBS Pedigrees and Delineation of
Critical Intervals
None of the pedigrees included in this study is large
enough to generate statistically significant positive LOD
scores with any marker. Therefore, with the exception
of mutational analysis of MKKS, it is not possible, in
any sibship, to assign the disorder to a locus by math-
ematical means. However, given that the known BBS
loci appear to account for nearly 90% of this syndrome
in the North American/European population, it is pos-
sible to assign individual loci in some pedigrees when
haplotype analysis excluded, in any given sibship, all but
one BBS locus (Katsanis et al. 1999). Using such as-
signments, we proceeded to delineate the different BBS
critical intervals through the identification of ancestral
recombinations (29 pedigrees) and/or loss of identity-
by-descent (IBD; 21 pedigrees) in families with dem-
onstrated or suspected consanguinity.
BBS2: Chromosome 16
Through haplotype construction of eight markers
spanning the known BBS2 critical interval, we deter-
mined that eight pedigrees were consistent with linkage
to 16q21. The haplotypes of all eight kindreds excluded
the other five loci, and thus increased the probability of
assignment to BBS2. The order of markers on chro-
mosome 16 and the relative position of recombinational
events or IBD are summarized in figure 2a. We detected
recombinations in three families: AR-029, AR-083, and
PB-005 (fig. 3a). In addition, AR-042 demonstrated a
region of IBD extending from D16S408 to D16S400.
Although this family is not known to be consanguineous,
both parents have maternal French-Acadian ancestry,
which may imply a founder mutation. The grandpater-
nal side of the family is less well documented but orig-
inates from the US-Canadian border. The other pedigrees
compatible with linkage of the disorder to BBS2 did not
contain recombinants across the marker set studied.
Taken together, these data suggest that BBS2 lies be-
tween D16S408 and D16S3057, a genetic distance of
∼2 cM, which, according to our physical maps of the
region, is ∼1.5 Mb; loss of IBD in AR-042 atD16S3057
further supports the distal boundary of this new critical
interval (fig. 2a). This represents a substantial reduc-
tion of the 18-cM critical interval reported elsewhere
(Kwitek-Black et al. 1993; Bruford et al. 1997).
BBS3: Chromosome 3
Using a similar analysis strategy, we identified two
pedigrees that were consistent with mapping of the dis-
order exclusively to the BBS3 locus. Analysis of these
pedigrees for markers in this critical interval revealed the
presence of a recombination in AR-201 individual -06
with marker D3S1566 and a distal recombination in an
unaffected individual -04 at marker D3S1251, suggest-
ing that BBS3 most likely lies between these two micro-
satellites (fig. 3b). These data substantially refine the
6-cM critical interval reported elsewhere (Young et
al. 1998) and refine the critical interval to between
D3S1603 and D3S1251, a distance of 2 cM or 1.1 Mb
(fig. 2b).
BBS4: Chromosome 15
Only a single pedigree, AR-287, has a haplotype pat-
tern consistent with linkage to chromosome 15 (BBS4)
(fig. 3c). All three affected individuals share a common
haplotype extending from D15S650 through D15S205,
a distance of 12 cM. We identified a recombination at
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Figure 1 Haplotype analysis of Newfoundland pedigree B14 with Hsa 16 (a) and Hsa 20 (b) markers from the critical intervals of BBS2
and BBS6. IBD markers from the BBS2 region are boxed. Note that individuals -03 and -04 have the same haplotypes for the BBS6 markers
tested and carry the same A242S alteration. Individuals -01 and -02 are second cousins.
D15S814 in individual -03, thus placing the BBS4 gene
distal to that marker. Bruford et al. (1997) narrowed the
interval to 2 cM through two recombinants, placing
BBS4 between D15S131 and D15S114; our interval
concurs with that of Bruford et al. (1997) (fig. 2c).
BBS5: Chromosome 2
Haplotype analysis of all 29 pedigrees suggests that
3 are consistent with linkage to chromosome 2q31. The
affected individuals from pedigrees AR-199, AR-273,
and AR-082 share haplotypes extending from D2S142
(cen) to D2S326 (tel) without recombination (fig. 2d).
This interval spans 13 cM or ∼7 Mb and does not
improve the original published interval derived from a
single Newfoundland family described by Young et al.
(1999a). Tests for heterogeneity were inconclusive be-
cause of the small numbers of pedigrees and their rel-
atively small size. However, if considered together, these
three pedigrees generate a two-point LOD score of 2.2.
Given that, in these pedigrees, linkage to all the other
loci could be excluded, our findings suggest the first
independent confirmation of the BBS5 locus on 2p31,
which, as expected, contributes only a small number of
BBS pedigrees to the syndrome.
BBS6: Chromosome 20
Since we were not able to detect the second mutation
in several pedigrees, despite the identification of an al-
teration that fulfilled all other genetic criteria of patho-
genicity, we analyzed other markers flankingMKKS.Of
the eight pedigrees containing likely BBS6 mutations,
four pedigrees of North American origin were compat-
ible with linkage to 20p12, two of which we described
elsewhere (Katsanis et al. 2000). One pedigree (NF-B14)
was expected to show linkage of the disorder to the
BBS2 locus; in the remaining pedigrees, the disorder
could not with confidence be excluded from one or more
other loci and thus no locus could be assigned, by our
criteria. Overall, according to our mutational analysis,
4% of pedigrees from our cohort show linkage of the
disorder to BBS6.
BBS7: Unknown
We performed genetic analyses of 27 pedigrees of
North American/European origin and of 2 Newfound-
land pedigrees in which linkage to BBS1 had previously
been excluded. Fifteen of these do not show convincing
evidence for linkage of the disorder to any of the known
BBS loci. We were unable to categorically exclude five
of them, owing to either small family size or uninform-
ative markers within some critical intervals. The re-
maining pedigrees ( ) represent 34% of this groupnp 10
of families, which did not initially show linkage to 11q13
as reported by Katsanis et al. (1999).When the pedigrees
with evidence for linkage to chromosome 11q13 and the
4% contribution of BBS6 are considered in the analysis,
the overall proportion of kindreds without linkage falls
to 14%, suggesting that one or more BBS loci remain
unmapped (fig. 4). Detailed analyses showed that, in two
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Figure 2 Schematic diagram of marker order on respective BBS chromosomal regions and the relative positions of recombination events
and extent of IBD. Arrowed lines depict extent of linkage, with the blunt end denoting recombination; solid graduated lines indicate regions
of IBD.
pedigrees (AR-707 and NF-B6), the disorder could be
excluded convincingly from all known loci both through
the generation of a LOD score of !2.0 and by hap-
lotype analysis, confirming the hypothesis that at least
one more BBS locus (BBS7) exists in the human genome.
Non-European IBD Study
We studied 12 Turkish families, 1 Iraqi family, 7 Pak-
istani families, and 1 East Indian family. Each affected
child was the result of a consanguineous union between
first-cousin parents; thus, haplotype analysis of BBS-af-
fected individuals should reveal IBD markers over part
or all of the critical region. If IBD was absent at any
locus, then that family was considered “unlinked” for
the purposes of this study. A total of 93 individuals were
genotyped with at least three markers spanning the most
recently published critical interval at each locus (BBS1-
6). Nine families had at least two affected members, 2
families had three affected members, and 10 families had
only a single affected member. Six pedigrees showed IBD
at consecutive markers from a single locus (table 2).
Three Turkish kindreds (each with a single affected in-
dividual)—PB-022, PB-023, and PB-024—demon-
strated IBD for two consecutive markers, D15S650 and
D15S204, and, in the case of PB-022 and PB-023, IBD
for an additional proximal marker, D15S814. Further-
more, all three pedigrees shared the same allele (119/
119) at D15S650, and PB-023 and PB-024 shared the
138 allele at D15S204. Since D15S814 is outside the
published critical interval (Bruford et al. 1997), we sug-
gest that BBS4 lies between D15S650 and D15S204, a
distance of 1.3 cM. Apart from PB-025, no other Turkish
pedigrees were IBD for any markers tested on 15q23. A
Pakistani family, PB-045, was exclusively IBD for all
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Table 2
Haplotypes of Consanguineous Pedigrees for Markers Encompassing the BBS2 and BBS4
Critical Regions
Critical Region
and Marker PB-022 PB-023 PB-024 PB-025 PB-044 PB-045 PB-046
BBS2:
D15S204 135/135 138/138 138/138 H 125/125 H 117/117
D15S650 119/119 119/119 119/119 123/123 135/135 H 135/135
D15S814 214/214 214/214 H 214/214 H H 218/218
D15S988 H H H H H H 268/268
BBS4:
D16S421 H H H H H 212/212 212/212
D16S400 H H H H H 198/198 198/198
D16S503 H H H H H 304/304 294/294
D16S408 H H H H H 247/247 247/247
NOTE.—Where homozygous, haplotypes are shown as allele sizes in bp; H p heterozygous
genotype.
four markers tested from the BBS2 locus (16q21),
whereas PB-044 was IBD for the two consecutive BBS4
markers D15S650 and D15S204. Although none of the
alleles were common to the Turkish kindreds, loss of
IBD at D15S814 concurs with the Turkish interval. Un-
expectedly, another Pakistani pedigree (PB-046) was IBD
for all markers from both the BBS2 and BBS4 intervals.
More importantly, however, we did not observe any con-
flicts in the critical interval as defined by haplotyping in
the outbred and consanguineous cohorts. Instead, we
have evidence of verification of the BBS2 and BBS4 crit-
ical intervals reported above and a potential reduction
of the BBS4 critical interval to 1.3 cM.
Discussion
Substantial difficulties arise in the determination of link-
age to any given gene locus in monogenic syndromes
such as BBS, in which the disorder is rare, recessive, and
genetically heterogeneous.We reported elsewhere the use
of haplotype analyses to delineate the BBS1 critical in-
terval (Katsanis et al. 1999). The major contribution of
that locus (40%–50%) to the syndrome allowed us to
apply a haplotyping strategy because of the high prob-
ability that, in each pedigree of North American/Euro-
pean origin, the disorder mapped to BBS1. Here, we
have addressed the much larger and more complicated
question of the global genetics of BBS. This issue is sub-
stantially more challenging because of both the smaller
contribution of each BBS locus and the fact that, in a
substantial fraction of pedigrees, the disorder cannot be
linked to any known locus. Despite these difficulties, we
were able to identify families consistent with linkage to
a single locus and thus propose refined boundaries for
several critical intervals. In addition, the recent identi-
fication of BBS6 allowed us to test the accuracy of this
haplotype technique. Of the eight pedigrees in which we
found mutations, seven were not associated previously
with any of the known loci through haplotype analysis,
but were classified as “locus unknown.” This suggests
that, although pedigrees are assigned to BBS loci
according to a best-fitting haplotype–deduced model
rather than absolute statistical criteria, these assignments
are accurate, which in turn increases our confidence in
the proposed delineation of the different BBS critical
intervals.
Newfoundland pedigree B14 was the only family in
which a known BBS6 mutation was observed but was
expected to map to chromosome 16, by virtue of IBD
across the BBS2 critical interval. However, both genetic
and mutational data suggest that the A242S alteration
may not conform to aMendelian model of disease trans-
mission. First, we were unable to identify a second mu-
tant allele. Second, and of greater importance, however,
both affected and unaffected sibs had the same chro-
mosome 20 haplotypes. One explanation for this might
be that the A242S allele does not cause BBS but is a
rare polymorphism. This conclusion would require that
the H84Y component of the complex Amish MKKS
allele is responsible for the phenotype. Alternatively,
A242S may not be fully penetrant, although we have
no evidence for such occurrence (there is no significant
skewing of the numbers of affected sibs in our cohort).
Finally, it is possible that A242S acts in conjunction
with mutations at another locus, which would explain
the family B14 haplotypes around BBS2, the inability
to identify a substantial proportion of the second disease
allele in patients with MKKS mutations, and the sig-
nificant fraction of pedigrees for which we cannot assign
the disorder to any locus. This model would not con-
stitute true digenic inheritance—since there must be two
mutations in BBS2, which, by themselves, are expected
to cause disease—but rather a modifier effect for some
MKKS mutations. Given that MKKS is a putative chap-
erone and may be a member of a multisubunit ring,
such a finding may not be surprising, since mutations
612
Figure 3 Pedigrees and haplotypes consistent with linkage to chromosomes (a) 16q21 (BBS2), (b) 3p13 (BBS3), and (c) 15q23.Recombination
events were observed in three pedigrees (AR-028,AR-083, andPB-005);when considered in combinationwith theproximalboundaryofhomozygosity
(IBD) in AR-042, the new critical interval is defined by markersD16S408 andD16S3057. Likewise, recombinations in AR-012 and AR-201 anchor
the boundaries for BBS3 at D3S1603 and D3S1271. A single pedigree (AR-287) was consistent with linkage to BBS4 on 15q23. A recombination
event in individual -03 defines an overlap with the interval reported by Bruford et al. (1997) but does not narrow it further.
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Figure 4 Summary of the approximate relative distribution of
each BBS locus in North American and European populations, based
on a haplotype-inferred locus assignment of pedigrees. Between the
present and the previous study (Katsanis et al. 1999), we obtained
genotype data for 92 pedigrees, which we used to calculate relative
contributions of each locus. Figures were then adjusted out of 96%
to account for the 4% contribution of BBS6, which was ascertained
by mutational analysis of a 163-patient cohort. In descending order
of prevalence, . NoteBBS1 1 BBS2 1 BBS6 1 BBS5 1 BBS3 1 BBS4
that as many as 14% of all pedigrees did not show linkage of the
disorder to any of the known loci; this, combined with the statistically
significant exclusion of linkage to BBS1–6 in families AR-707 andNF-
B6, is highly suggestive of at least a seventh BBS locus.
in either multiple members of the ring and/or interacting
proteins may further reduce the efficiency of binding
and may result in more-severe phenotypes.
Pedigree NF-B14 does exhibit a severe phenotype,
since the patients present with all the BBS features as
well as early age at onset. However, given the substantial
clinical heterogeneity of the syndrome, we must inter-
pret these data with caution until additional BBS genes
and a substantial number of pedigrees exhibiting this
complex pattern of inheritance are identified. Intrigu-
ingly, two of the three pedigrees in which a single BBS6
mutation was found and the pedigree structure was
large enough to allow linkage studies (AR-259 and AR-
301) are expected to show linkage of the disorder to
chromosome 15. AR-259 is also homozygous for the
distal portion of the BBS4 critical region; in the third
pedigree, AR-127, linkage was excluded from all known
BBS loci.
In contrast to the BBS6-causing mutations reported
elsewhere, most of which were frameshifts with an ob-
vious deleterious effect on the protein, all mutations
reported here are missense mutations. Therefore, it is
more difficult to predict their effect on the MKKS mol-
ecule; nevertheless, most alterations are likely to affect
either local polarity or the secondary or tertiary struc-
ture of the protein (table 1). Notably, three of the mu-
tations lie in exon 6 of MKKS, which contradicts the
hypothesis that exon 3 mutations are more severe and
thus cause BBS rather than MKKS (Katsanis et al. 2000;
Slavotinek et al. 2000).
Through a combination of haplotype analysis and
homozygosity mapping, we assigned 14 North Ameri-
can/European families and six non-European families
to BBS2–5. Thereby, the potential critical interval on
chromosome 16q21 is reduced to a size amenable to
positional cloning. We have also confirmed the BBS5
locus on 2q31, previously reported in a single New-
foundland family (Young et al. 1999a), by adding three
new pedigrees. Originally, BBS3 on 3p13 was mapped
by homozygosity techniques in a single, large Bedouin
pedigree and was later confirmed in the same way in a
single Newfoundland family (Sheffield et al. 1994;
Young et al. 1998). Two of our North American families
have haplotypes uniquely consistent with mapping to
BBS3, and both serve to reduce the critical interval to
2 cM.
In light of the report by Bruford et al. (1997) in which
8 (35%) of 29 pedigrees from northern Europe showed
linkage of the disorder to chromosome 15, it is sur-
prising that only one of our European pedigrees is con-
sistent with linkage to BBS4.However, five Turkish and
Pakistani pedigrees showed IBD to BBS4, suggesting
that there may be a more prevalent founder locus in
these populations and that perhaps the best chance for
identification of this gene may be through homozygosity
mapping in Middle Eastern/Asian consanguineous
kindreds.
Of interest, PB-046 was IBD for all markers in both
the BBS2 and BBS4 intervals. We may interpret this in
two ways: (1) This was a chance occurrence. Given that
the parents are first cousins, they would be predicted to
be IBD at two random but different loci 1/16 times and
might have a homozygous putative alteration at either
one of the two loci. However, dual incidences of IBD
were not seen in any other consanguineous pedigree in
this study. Alternatively, (2) this pedigree contains two
homozygous mutations on different loci (pseudo-di-
genic inheritance), any one of which might be sufficient
to lead to BBS by itself. As with NF-B14, where pseudo-
digenic inheritance or a modifier effect of BBS6 is spec-
ulated, we cannot attempt a genotype-phenotype cor-
relation because of the substantial clinical variability of
the syndrome.
Since the recent identification of BBS6, this is the first
study to define the prevalence of mutations in MKKS
among BBS pedigrees from North America and Europe.
In contrast to Newfoundland, where BBS6 accounts for
the disorder in 40% of all families with BBS, our data
show that only 4% of North American/European fam-
ilies with BBS have mutations in MKKS. We have also
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accurately determined the overall distribution of BBS
loci (fig. 4) by analysis of a large number of families
from diverse populations.We have concluded thatBBS1
and BBS2 account for the majority of cases among the
North American/European population group, whereas
BBS4 is most prevalent among this population subset
of Turks and Pakistanis. Of interest, the proportion of
unassigned pedigrees in the latter cohort is very high
(62%), suggesting that this population may still contain
either a hitherto unidentified high-prevalence single lo-
cus or multiple minor loci.
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